Ascendis Pharma A/S vs Upstart Holdings Inc — how do they compare? Ascendis Pharma A/S trades at $255.5 (market cap $16.67B), while Upstart Holdings Inc trades at $30.22 (market cap $2.91B). The key difference: Ascendis Pharma A/S is far larger — about 5.7× Upstart Holdings Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ASND | UPST | |
|---|---|---|
Market Cap | $16.67B | $2.91B |
Sector | Health | Financials |
52-Week High | $277.18 | $73.76 |
52-Week Low | $189.74 | $24.22 |
Enterprise Value | $17.04B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Upstart Holdings trades at $30.21, down 2.83% on the day, with a bullish technical signal supported by moving averages despite recent earnings misses. The company achieved a significant turnaround with $53.6M net income in 2025 after years of losses, driven by 42% revenue growth in Q2 2026. Analyst consensus remains positive with a $47.20 price target, though debt levels have risen to 61.48% of assets.
The outlook balances strong AI-driven loan growth against execution risks and high valuation. Near-term catalysts include the upcoming bank launch and sustained origination growth, while macroeconomic sensitivity and competitive pressures present ongoing challenges for the lending platform.
Trailing returns across standard periods
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →